Statin-Induced Toxic Myopathy Masquerading as Recurrent Falls and De-Conditioning in an Older Adult
Main Article Content
Keywords
Statin-induced myopathy, Proximal muscle weakness, Elderly patients, Atorvastatin toxicity
Abstract
Statins, widely prescribed for their efficacy in reducing low-density lipoprotein cholesterol (LDL-C) and preventing atherosclerotic cardiovascular disease, are generally well tolerated. However, muscle-related adverse effects, particularly statin-associated myopathy, can significantly impact patient function and adherence. This case report describes an 83-year-old man who developed progressive proximal muscle weakness, fatigue, and recurrent falls following initiation of high-dose atorvastatin after a ST-elevation myocardial infarction. Clinical and laboratory evaluation, along with the temporal association and improvement after drug withdrawal, supported a diagnosis of self-limited toxic statin myopathy. Extensive differential diagnosis excluded other neuromuscular, endocrine, and vascular causes. Prompt discontinuation of atorvastatin, supportive care, and physiotherapy led to marked functional recovery. This case highlights the spectrum of statin-induced muscle toxicity, emphasises diagnostic vigilance in older adults, and underscores the importance of personalised therapy and early intervention to mitigate adverse outcomes.
References
2. Attardo S, et al. Statins Neuromuscular Adverse Effects. Int J Mol Sci. 2022;23(15):8364. https://doi.org/10.3390/ijms23158364
3. Selva-O’Callaghan A, et al. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol. 2018;14(3):215–224. https://doi.org/10.1080/1744666x.2018.1440206
4. Hansen KE, et al. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165(22):2671. https://doi.org/10.1001/archinte.165.22.2671
5. Reddy Somagutta M, et al. Statin-induced necrotizing autoimmune myopathy: a systematic review. Rheumatology. 2022;60(1):63–69. https://doi.org/10.5114/reum.2022.114108
6. Khan F, et al. Challenges in the diagnosis and management of immune-mediated necrotising myopathy (IMNM). Rheumatol Int. 2022. https://doi.org/10.1007/s00296-022-05230-0
7. Mollazadeh H, et al. Effects of statins on mitochondrial pathways. J Cachexia Sarcopenia Muscle. 2021;12(2). https://doi.org/10.1002/jcsm.12654
8. Liu M, et al. The association of GATM polymorphism with statin-induced myopathy. Eur J Clin Pharmacol. 2021;77(3):349–357. https://doi.org/10.1007/s00228-020-03019-3
9. Yee J, et al. Association between CYP3A5 polymorphism and statin-induced adverse events. J Pers Med. 2021;11(7):677. https://doi.org/10.3390/jpm11070677
10. Tariq S, et al. Correlates of myopathy in diabetic patients taking statins. Cureus. 2023. https://doi.org/10.7759/cureus.37708
11. Cobos-Palacios L, et al. Statin Therapy in Very Old Patients: Lights and Shadows. Front Cardiovasc Med. 2021;8. https://doi.org/10.3389/fcvm.2021.779044
12. Zheng H, et al. Statin use and fall risk in adults: a cross-sectional survey and Mendelian randomization analysis. Front Pharmacol. 2024;15. https://doi.org/10.3389/fphar.2024.1364733
13. World Health Organization. Falls. 2021. Available: https://www.who.int/news-room/fact-sheets/detail/falls
14. Gaist D, et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology. 2001;12(5):565–569. https://doi.org/10.1097/00001648-200109000-00017
15. Suppamutharwyam M, Shah TM. Statin-Associated Autoimmune Myopathy Masquerading As Recurrent Falls in an Older Adult. Cureus. 2023. https://doi.org/10.7759/cureus.45515
16. Zeng W, et al. Advances in statin adverse reactions and the potential mechanisms: A systematic review. J Adv Res. 2024. https://doi.org/10.1016/j.jare.2024.12.020
17.European Society of Cardiology (ESC). 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. ESC Clinical Practice Guidelines. Eur Heart J. 2021;42(34):3227–3377.
18.National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guideline [NG238]. London: NICE; 2023. Available from: https://www.nice.org.uk/guidance/ng238
19.Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This is an open-access journal and articles are distributed under the terms of the Creative Commons Attribution Non-Commercial Share-Alike License 4.0. This licence allows users to download and share, remix, tweak and build upon the article for non-commercial purposes, so long as the original authorship is acknowledged and the new creations are licensed under identical terms.